Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Positive interim results for Tryptamine’s trial of oral psilocybin to treat IBS
Health & Biotech
Tryptamine’s psilocin infusion study reveals solid results in obese
Health & Biotech
Could Trump’s second act boost these ASX psychedelic stocks?
Health & Biotech
Tryptamine completes psilocin-based IV-infusion study in obese subjects
Health & Biotech
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study
Health & Biotech
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health fallout
Health & Biotech
Health Check: Actinogen powers ahead with key Alzheimer’s disease trial
Stockhead TV
Break it Down: Cash in the bag for Tryptamine Therapeutics
News
ASX Small Caps Lunch Wrap: (Super)markets fall on Aussie inflation data; goldies still gleaming
Health & Biotech
Tryptamine raises $6 million to advance world-first IV psilocin drug
News
Rise and Shine: Everything you need to know before the ASX opens
Stockhead TV
Tony’s Takeaway: Psychedelic stocks
News
Closing Bell: ASX falls while Flight Centre flags turbulence ahead
Stockhead TV
Break it Down: Tryptamine Therapeutics’ moves closer to IV-infused psilocybin treatment
Health & Biotech
‘Significant derisking catalyst’: Tryptamine’s world-first IV psilocin drug found safe
Health & Biotech
ASX innovators reshaping traditional medical treatments
Health & Biotech
